在全球医药研发服务（CRO/CDMO）行业竞争加剧、产业链重构的背景下，睿智医药（300149.SZ）加 速推进全球化与技术转型战略。2025年9月随着波士顿研发中心正式启用，睿智医药全球化创新布局再 添强劲引擎——通过国际化的研发平台建设，深化与全球合作伙伴的技术协同，为创新药物研发注入新 动能。 贴近市场，融入创新生态 作为睿智医药"全球布局，本地服务"战略的重要落子，波士顿研发中心具备多重核心优势。在战略区位 方面，其位于波士顿生物科技产业走廊核心区域，可与全球顶尖药企、生物科技公司构建"创新共同 体"，深度融入全球生命科学创新高地；在服务能力上，中心能够提供从生物药发现、药理学研究到 DMPK服务的全链条解决方案，覆盖早期发现至IND申报的全周期，还可为北美客户提供符合标准的本 地化服务，有效规避跨境物流限制；在硬件与人才方面，中心占地13,800平方英尺，配备国际一流的实 验设备，由资深科学家团队领衔。 睿智医药董事长兼CEO胡瑞连表示："随着行业对本地化、敏捷化研发合作需求的增长，我们在波士顿 建立研发中心，正是为了突破地域限制，实现与客户的'零距离'协作。我们期待为合作伙伴提供更高 效、更个性化 ...

Core Insights - The article discusses the transformation of Ruizhi Pharmaceutical, a veteran in China's CRO industry, under the leadership of Chairman Hu Ruilian, highlighting its recovery from a four-year cumulative loss of 2.2 billion yuan to achieving a revenue of 534 million yuan in the first half of 2025, representing a year-on-year growth of 14.75% [1][3]. Company Overview - Ruizhi Pharmaceutical, once a leading player in the CRO sector, faced significant challenges due to management instability, resulting in a strategic shift towards focusing on customer needs and technological innovation [2][3]. - The company has established three core strategies: focusing on new modalities such as ADC, small nucleic acids, and peptides; promoting integrated service models; and expanding globally with new research centers in Boston and a biopharmaceutical industrial park in Malaysia [3][6]. Industry Trends - The CRO industry is experiencing a shift from rapid expansion to high-quality development, with a growing demand for differentiated innovation and high-quality data from clients [4][8]. - The integration of AI in drug development has become essential, optimizing processes and increasing efficiency throughout the research and development cycle [6][7]. Market Dynamics - The demand for end-to-end services is rising, as clients prefer comprehensive solutions that streamline processes and enhance international collaboration [4][7]. - The Chinese CRO sector is transitioning from a cost-driven model to one focused on technological advantages, with companies like Ruizhi Pharmaceutical now capable of competing on a global scale in advanced fields such as ADC and small nucleic acids [8][9]. Future Outlook - The article emphasizes that the opportunities for Chinese CROs are greater than the challenges, particularly in the context of global supply chain restructuring and the increasing need for reliable partners in the pharmaceutical industry [9]. - The future success of Chinese CROs will depend on their ability to transition from "Made in China" to "Intelligent Manufacturing in China," leveraging technology and global partnerships to become integral players in the global innovation drug supply chain [9].

Core Insights - The establishment of the Boston R&D Center marks a significant milestone in the global strategic layout of the company, enhancing its international collaboration and innovation capabilities in drug development [1][3][4] Group 1: Boston R&D Center - The Boston R&D Center is strategically located in the heart of the Boston biotech corridor, facilitating deep integration with leading pharmaceutical companies and research institutions [4] - The center offers comprehensive R&D services covering the entire chain from early discovery to IND application, helping North American clients avoid cross-border logistics limitations and shorten development cycles [4] - The facility spans 13,800 square feet and is equipped with world-class laboratory equipment, led by a team of experienced scientists [4] Group 2: Leadership and Vision - The company's Chairman and CEO, Hu Ruilian, emphasized the need for localized and agile R&D collaborations to meet the growing industry demand [4][6] - Hu Ruilian articulated the company's vision to inject strong momentum into local and global life sciences innovation through its leading technological capabilities and full-chain service offerings [6] Group 3: Financial Performance - The company reported a revenue of 534 million yuan for the first half of 2025, representing a year-on-year growth of 14.75%, with a net profit of 25.38 million yuan, a significant increase of 140.35% [12] - The gross margin for the pharmaceutical R&D services and production business improved to 29.17%, with specific revenue growth in efficacy and pharmacokinetics services by 13.44% and large molecule services by 54.68% [12] Group 4: Strategic Transformation - The company is transitioning from traditional CRO services to a full-chain CXO service model, focusing on a one-stop service platform from target discovery to IND [13] - The strategic shift includes enhancing investments in new modality drug development and AI technology applications to expand business boundaries and improve core competitiveness [13] - Hu Ruilian stated that the establishment of the Boston R&D Center is a strategic move to achieve zero-distance collaboration with clients amid industry uncertainties and high R&D costs [13]

为进一步加强与投资者的互动交流，睿智医药科技股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价值 领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会" 活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五） 15:30-17:00。届时公司高管将在线就 2025 年半年度业绩、公司治理、发展战略、 经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与。 证券代码：300149 证券简称：睿智医药 公告编号：2025-66 睿智医药科技股份有限公司 关于参加广东辖区 2025 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 睿智医药科技股份有限公司 董事会 2025 年 9 月 16 日 ...

Company Overview - RuiZhi Pharmaceutical is located in Guangzhou, Guangdong Province, and was established on January 26, 2000. The company was listed on December 22, 2010. Its main business involves pharmaceutical research and production outsourcing services, micro-ecological nutrition, and micro-ecological medical services [1][2]. Financial Performance - For the first half of 2025, RuiZhi Pharmaceutical achieved operating revenue of 534 million yuan, representing a year-on-year growth of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, showing a significant increase of 140.35% year-on-year [2]. - Since its A-share listing, RuiZhi Pharmaceutical has distributed a total of 180 million yuan in cash dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 15, RuiZhi Pharmaceutical's stock price increased by 2.01%, reaching 13.67 yuan per share, with a total market capitalization of 6.807 billion yuan. The stock has risen by 112.93% year-to-date [1]. - The stock has experienced a slight decline of 0.58% over the past five trading days, but has increased by 1.79% over the past 20 days and by 24.16% over the past 60 days [1]. Shareholder Information - As of August 8, the number of shareholders for RuiZhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period. The average number of circulating shares per person increased by 23.28% to 9,038 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 24.33 million shares, with no change in the number of shares held compared to the previous period [3]. Market Position - RuiZhi Pharmaceutical operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing. The company is involved in various concept sectors, including Alzheimer's, biopharmaceuticals, peptide drugs, innovative drugs, and cancer treatment [2].

Group 1 - The stock price of Ruizhi Pharmaceutical (300149) closed at 13.26 yuan on September 12, 2025, with an increase of 2.39% and a turnover rate of 6.02% [1] - On September 12, 2025, the net inflow of main funds was 20.86 million yuan, indicating increased short-term interest from major investors [2][4] - The company plans to issue shares to a specific investor, Ruilian Investment, at a price of 5.27 yuan per share, with a maximum issuance of 60,019,704 shares, aiming to raise up to 316.30 million yuan for working capital and bank loan repayment [2][4] Group 2 - The issuance will not change the company's control, with the actual controller remaining WOO SWEE LIAN, and after the issuance, Ruilian Investment will hold a 15.53% stake, becoming the controlling shareholder [2] - The application for the share issuance has been accepted by the Shenzhen Stock Exchange, and the updated documents were disclosed on the same day as the half-year report [2] - The issuance is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2]

Core Viewpoint - The article discusses the transformation and strategic adjustments of Ruizhi Pharmaceutical, a veteran in China's CRO industry, under the leadership of Chairman Hu Ruilian, highlighting the company's recovery from significant losses and its focus on innovation and customer needs in a changing market landscape [1][4]. Company Overview - Ruizhi Pharmaceutical, once a leading player in the CRO industry, faced a cumulative loss of 2.2 billion yuan over four years due to management instability and strategic misalignment [3][4]. - In 2025, the company reported a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, with a significant improvement in gross margin [1][4]. Strategic Adjustments - The company has established three core strategies: focusing on new modalities such as ADCs, small nucleic acids, and peptides; promoting integrated service models; and expanding globally with new research centers in Boston and a biopharmaceutical park in Malaysia [4][6]. - The shift towards a customer-centric approach emphasizes the importance of meeting client demands for differentiated innovation and high-quality data [5][6]. Market Trends - The Chinese innovative drug market is projected to exceed 400 billion yuan in 2024, indicating a shift from rapid expansion to high-quality development, which impacts the demand for CRO services [4][6]. - The CRO industry is experiencing a transformation driven by client demands for integrated services and advanced technology platforms, particularly for new drug modalities [5][6]. Future Outlook - The integration of AI in drug development is becoming essential, with expectations for CROs to enhance their capabilities in this area [7][8]. - The global pharmaceutical supply chain is being reshaped by geopolitical factors, creating opportunities for Chinese CROs to become reliable partners in global supply chains [9]. - The future success of Chinese CROs hinges on their ability to transition from "Made in China" to "Intelligent Manufacturing in China," leveraging technology and global partnerships [9].

睿智医药科技股份有限公司 审计报告及财务报表 二〇二四年度 信会师报字[2025]第 Z110429 号 码用于证明该审计报告是否由具有执业许可的会计师事务所出具 "册会计师行业统一监管买台（http://acc.mof.gov.cn） 进行查验 您可使用手机"扫一扫"或进入 台(http://acc.mof.gov.cn) 进 睿智医药科技股份有限公司 审计报告及财务报表 (2024年 01月 01 日至 2024 年 12 月 31 日止) | | 目录 | 页次 | | --- | --- | --- | | | 审计报告 | 1-5 | | | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-96 | | 11 | 事务所及注册会计师执业资质证明 | | 6-1-2 立信会计师事务所(特殊普通合1 HINA SHU LUN PAN CERTIFIED PUBLIC A ...

证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司 （Chempartner Pharmatech Co.,Ltd.） （广东省江门市江海区胜利南路 164 号） 2024 年度向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年九月 声 明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责，投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引 ...

中信证券股份有限公司 关于 睿智医药科技股份有限公司 2024 年度向特定对象发行股票 之 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 2025 年 9 月 睿智医药科技股份有限公司 上市保荐书 声 明 中信证券股份有限公司（以下简称"中信证券"、"保荐人"或"本保荐 人"）及其保荐代表人周游、王栋根据《中华人民共和国公司法》（下称《公司 法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上市公司证 券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市保荐 业务管理办法》（以下简称"《保荐管理办法》"）等有关法律、法规和中国证 券监督管理委员会（以下简称"中国证监会"）的有关规定以及深圳证券交易所 （以下简称"深交所"）的有关业务规则，诚实守信，勤勉尽责，严格按照依法 制定的业务规则和行业自律规范出具本上市保荐书，并保证上市保荐书的真实、 准确、完整。 如无特别说明，本上市保荐书中所涉简称与《睿智医药科技股份有限公司 2024 年度向特定对象发行股票募集说明书》一致。 3-3-1 | | 的控股股东、实际控制人、重要关联方相互提供担保或者 ...